Clinical Trial

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Study acronym: ALFA2101
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-02-17; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2023-05-03
Trial Details
NCT Number NCT05260528
Lead Sponsor Centre Hospitalier Universitaire de Nice
Collaborators: Jazz Pharmaceuticals, Acute Leukemia French Association
Conditions Acute Myeloid Leukemia
Enrollment 248 participants
Start Date 2023-05-03
Primary Completion 2028-08-02 (estimated)
Study Completion 2030-02-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-27